Part B of the trial will enroll nine adult patients as well as three pediatric patients.

ARVO 2025 Highlight: PYC Reports Encouraging Phase 1/2 Clinical Trial Results for its RNA Therapy Targeting RP (PRPF31 Mutations)

The Foundation Fighting Blindness is the driving force in the global development of treatments and cures for blinding diseases. To learn more, go to FightingBlindness.org.